Elicio Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $17.00K, a 66.00% decline year-over-year.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $100.00K, a 1328.57% increase year-over-year.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $88.00K, a 319.05% increase year-over-year.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $50.00K, a 284.62% increase year-over-year.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $149.00K, a 282.05% increase from fiscal 2024.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $39.00K, a 69.29% decline from fiscal 2023.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $127.00K, a 1714.29% increase from fiscal 2022.
- Elicio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $7.00K, a 99.29% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $17.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $100.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $149.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $88.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $50.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $7.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $39.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $21.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $13.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $127.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $60.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $40.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $7.00K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $4.00K 10-Q · filed 2023-11-13 | $122.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $3.00K 10-Q · filed 2023-11-13 | $904.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-03-31 | $1.00K 10-Q · filed 2023-11-13 | $980.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2021-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $980.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $786.00K 10-Q · filed 2022-11-14 | $875.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $79.00K 10-Q · filed 2022-11-14 | $126.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | $1.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $47.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $37.00K 10-Q · filed 2021-11-12 | |
| 2020-03-31 | -$1.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |